Salas-Delgado A, Hernández-Pliego AM

Language: Spanish
References: 14
Page: 276-281
PDF size: 139.52 Kb.

ABSTRACT

Background: The overall survival and relapse-free survival have increased with current chemotherapy in patients with non-lymphoma Hodgkin. A useful tool to evaluate projections is the International Prognostic Index. Our aim was to evaluate the relation between the prognosis established with the International Prognostic Index and the survival obtained in two years by patients with diffuse large B-cell lymphoma.
Methods: An observational, longitudinal, prospective study was carried out. Patients included were those with diagnosis and treated along a year, who, at some point in their evolution, required hospitalization. All the patients received ciclofosfamide, doxorrubicine, vincristine and prednisone; additionally, some of them received rituximab. The follow-up average was 26 months. Survival was estimated with Kaplan-Meier curves.
Results: Forty-nine patients were included and classified according to the International Prognostic Index risk. The survival was 90 % for patients with International Prognostic Index low risk, 66.7 % for the patients with intermediate-low risk, 80 % for patients with intermediate-high risk, and 81 % for patients with high risk. The survival for all risk groups was 77.6 %. When we compared the survival of patients with the expected prognosis through the International Prognostic Index, we obtained p = 0.0000.
Conclusions: Two years after diagnosis, the survival of patients with diffuse large B-cell lymphoma in the study was better than the prognosis estimated through the International Prognostic Index, and similar to that reported in American studies.

REFERENCES

1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265-76. Disponible en http://www. ncbi.nlm.nih.gov/pmc/articles/PMC1895348/

2. Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by subtype: A report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105(11):1684- 92. Disponible en http://www.nature.com/bjc/journal/ v105/n11/full/bjc2011450a.html

3. Laurini JA, Perry AM, Boilesen E, Diebold J, Maclennan KA, Müller-Hermelink HK, et al. Classifi cation of non-Hodgkin lymphoma in Central and South America: A review of 1028 cases. Blood. 2012;20 (24):4795-801.

4. Shenoy PJ, Malik N, Nooka A, Sinha R, Ward KC, Brawley OW, et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer. 2011;117(11): 2530-40.

5. A clinical evaluation of the International Lymphoma Study Group classifi cation of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classifi cation Project. Blood. 1997;89(11):3909-18.

6. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classifi cation Project. J Clin Oncol. 1998;16(8)2780-95.

7. Yamaguchi M, Seto M, Okamoto M, Ichinohasama R, Nakamura N, Yoshino T, et al. De novo CD5+ diffuse large B-cell lymphoma: A clinicopathologic study of 109 patients. Blood. 2002;99(3):815-21.

8. Barrans SL, O’Connor SJ, Evans PA, Davies FE, Owen RG, Haynes AP, et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol. 2002;117(2):322-32.

9. Bouabdallah R, Mounier N, Guettier C, Molina T, Ribrag V, Thieblemont C, et al. T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis. J Clin Oncol. 2003;21(7):1271-7.

10. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987-94.

11. Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28(14):2373-80.

12. Moller MB, Pedersen NT, Christensen BE. Factors predicting long-term survival in low-risk diffuse large B-cell lymphoma. Am J Hematol. 2003;74(2):94-8.

13. Cortelazzo S, Rossi A, Roggero F, Oldani E, Zucca E, Tondoni C, et al. Stage-modifi ed international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group (IELSG). Ann Oncol. 1999; 10(12):1433-40.

14. Cortelazzo S, Rossi A, Oldani E, Oldani E, Zucca E, Tondini C, et al. The modifi ed International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies. Br J Haematol. 2002;118(1):218-28.